Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA

C. C. Carpenter, M. A. Fischl, S. M. Hammer, M. S. Hirsch, D. M. Jacobsen, D. A. Katzenstein, J. S. Montaner, D. D. Richman, M. S. Saag, R. T. Schooley, M. A. Thompson, S. Vella, P. G. Yeni and P. A. Volberding
Brown University School of Medicine, Providence, RI, USA.

OBJECTIVE--To provide clinical recommendations for antiretroviral therapy for human immunodeficiency virus (HIV) disease with currently (mid 1996) available drugs. When to start therapy, what to start with, when to change, and what to change to were addressed. PARTICIPANTS--A 13-member panel representing international expertise in antiretroviral research and HIV patient care was selected by the international AIDS Society-USA. EVIDENCE--Available clinical and basic science data, including phase 3 controlled trials, clinical endpoint data, virologic and immunologic endpoint data, interim analyses, studies of HIV pathophysiology, and expert opinions of panel members were considered. Recommendations were limited to drugs available in mid 1996. PROCESS--For each question posed, 1 or more member(s) reviewed and presented available data. Recommendations were determined by group consensus (January 1996); revisions as warranted by new data were incorporated by group consensus (February-May 1996). CONCLUSIONS--Recent data on HIV pathogenesis, methods to determine plasma HIV RNA, clinical trial data, and availability of new drugs point to the need for new approaches to treatment. Therapy is recommended based on CD4+ cell count, plasma HIV RNA level, or clinical status. Preferred initial drug regimens include nucleoside combinations; at present protease inhibitors are probably best reserved for patients at higher progression risk. For treatment failure or drug intolerance, subsequent regimen considerations include reasons for changing therapy, available drug options, disease stage, underlying conditions, and concomitant medication(s). Therapy for primary (acute) infection, high-risk exposures to HIV, and maternal-to-fetal transmission are also addressed. Therapeutic approaches need to be updated as new data continue to emerge.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Antiretroviral Treatment of Adult HIV Infection: 2008 Recommendations of the International AIDS Society-USA Panel
Hammer et al.
JAMA 2008;300:555-570.
ABSTRACT | FULL TEXT  

Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements
Jimenez-Nacher et al.
J Antimicrob Chemother 2008;0:dkn252v1-7.
ABSTRACT | FULL TEXT  

How Do Subjectively-Constructed Meanings Ascribed to Anti-HIV Treatments Affect Treatment-Adherent Practice?
Wong and Ussher
Qual Health Res 2008;18:458-468.
ABSTRACT  

The Effect of Care Team Composition on the Quality of HIV Care
Rodriguez et al.
Med Care Res Rev 2008;65:88-113.
ABSTRACT  

Treatment for Adult HIV Infection: 2006 Recommendations of the International AIDS Society-USA Panel
Hammer et al.
JAMA 2006;296:827-843.
ABSTRACT | FULL TEXT  

Biological characterization of human immunodeficiency virus type 1 subtype C protease carrying indinavir drug-resistance mutations.
Gonzalez et al.
J. Gen. Virol. 2006;87:1303-1309.
ABSTRACT | FULL TEXT  

Eosinophilic Folliculitis: Before and After the Introduction of Antiretroviral Therapy
Rajendran et al.
Arch Dermatol 2005;141:1227-1231.
ABSTRACT | FULL TEXT  

A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study)
Orkin et al.
J Antimicrob Chemother 2005;55:246-251.
ABSTRACT | FULL TEXT  

Clinical Trials in Sub-Saharan Africa and Established Standards of Care: A Systematic Review of HIV, Tuberculosis, and Malaria Trials
Kent et al.
JAMA 2004;292:237-242.
ABSTRACT | FULL TEXT  

Treatment for Adult HIV Infection: 2004 Recommendations of the International AIDS Society-USA Panel
Yeni et al.
JAMA 2004;292:251-265.
ABSTRACT | FULL TEXT  

Starting highly active antiretroviral therapy: why, when and response to HAART
Mocroft and Lundgren
J Antimicrob Chemother 2004;54:10-13.
ABSTRACT | FULL TEXT  

Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users
Wood et al.
CMAJ 2003;169:656-661.
ABSTRACT | FULL TEXT  

The XIV International AIDS Conference: a call for action ... now
Berger
CMAJ 2002;167:483-484.
FULL TEXT  

Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy
Jordan et al.
BMJ 2002;324:757-757.
ABSTRACT | FULL TEXT  

Rates of Disease Progression by Baseline CD4 Cell Count and Viral Load After Initiating Triple-Drug Therapy
Hogg et al.
JAMA 2001;286:2568-2577.
ABSTRACT | FULL TEXT  

Differences in the Temporal Trends of HIV Seroincidence and Seroprevalence among Sexually Transmitted Disease Clinic Patients, 1989-1998: Application of the Serologic Testing Algorithm for Recent HIV Seroconversion
Schwarcz et al.
Am J Epidemiol 2001;153:925-934.
ABSTRACT | FULL TEXT  

Immunologic dynamics in hemophiliac patients infected with hepatitis C virus and human immunodeficiency virus: influence of antiretroviral therapy
Yokozaki et al.
Blood 2000;96:4293-4299.
ABSTRACT | FULL TEXT  

Acquired Immunodeficiency Syndrome-Related Kaposi's Sarcoma Regression After Highly Active Antiretroviral Therapy: Biologic Correlates of Clinical Outcome
Cattelan et al.
J Natl Cancer Inst Monogr 2000;2000:44-49.
ABSTRACT | FULL TEXT  

Differential Access in the Receipt of Antiretroviral Drugs for the Treatment of AIDS and Its Implications for Survival
Anderson and Mitchell
Arch Intern Med 2000;160:3114-3120.
ABSTRACT | FULL TEXT  

Rebuilding Life: The Experience of Living with AIDS after Facing Imminent Death
Trainor and Ezer
Qual Health Res 2000;10:646-660.
ABSTRACT  

The significance of oral health in HIV disease
Chapple and Hamburger
Sex. Transm. Infect. 2000;76:236-243.
FULL TEXT  

Why Don't Patients and Physicians Talk About End-of-Life Care?: Barriers to Communication for Patients With Acquired Immunodeficiency Syndrome and Their Primary Care Clinicians
Curtis et al.
Arch Intern Med 2000;160:1690-1696.
ABSTRACT | FULL TEXT  

Health-Related Quality of Life in Persons Younger and Older than 50 Who are Living with HIV/AIDS
Nokes et al.
Research on Aging 2000;22:290-310.
ABSTRACT  

Applications of Flow Cytometry to Clinical Microbiology
Alvarez-Barrientos et al.
Clin. Microbiol. Rev. 2000;13:167-195.
ABSTRACT | FULL TEXT  

Highly Active Antiretroviral Therapy for Patients with AIDS Dementia Complex: Effect on MR Imaging Findings and Clinical Course
Thurnher et al.
Am. J. Neuroradiol. 2000;21:670-678.
ABSTRACT | FULL TEXT  

Antiretroviral Therapy in Adults: Updated Recommendations of the International AIDS Society-USA Panel
Carpenter et al.
JAMA 2000;283:381-390.
ABSTRACT | FULL TEXT  

Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults
Staszewski et al.
NEJM 1999;341:1865-1873.
ABSTRACT | FULL TEXT  

Is Experience With Human Immunodeficiency Virus Disease Related to Clinical Practice?: A Survey of Rural Primary Care Physicians
Willard et al.
Arch Fam Med 1999;8:502-508.
ABSTRACT | FULL TEXT  

HIV Testing, Drug Use, and STD Prevalence Among Juveniles Entering a Rhode Island Correctional Facility
Pugatch et al.
JOURNAL OF CORRECTIONAL HEALTH CARE 1999;6:197-205.
ABSTRACT  

The Medical Evaluation of the Sexually Abused Child: Lessons From a Decade of Research
Atabaki and Paradise
Pediatrics 1999;104:178-178.
FULL TEXT  

Variations in the Care of HIV-Infected Adults in the United States: Results From the HIV Cost and Services Utilization Study
Shapiro et al.
JAMA 1999;281:2305-2315.
ABSTRACT | FULL TEXT  

Constant Mean Viral Copy Number per Infected Cell in Tissues Regardless of High, Low, or Undetectable Plasma HIV RNA
Hockett et al.
J. Exp. Med. 1999;189:1545-1554.
ABSTRACT | FULL TEXT  

Current Concepts in Human Immunodeficiency Virus Infection and AIDS
Schwartz and Nair
CVI 1999;6:295-305.
FULL TEXT  

Reproducibility and Performance of the Second-Generation Branched-DNA Assay in Routine Quantification of Human Immunodeficiency Virus Type 1 RNA in Plasma
Murphy et al.
J. Clin. Microbiol. 1999;37:812-814.
ABSTRACT | FULL TEXT  

Tuberculosis in Patients with Human Immunodeficiency Virus Infection
Havlir and Barnes
NEJM 1999;340:367-373.
FULL TEXT  

Intracellular Nucleotides of (-)-2',3'-Deoxy-3'-Thiacytidine in Peripheral Blood Mononuclear Cells of a Patient Infected with Human Immunodeficiency Virus
Solas et al.
Antimicrob. Agents Chemother. 1998;42:2989-2995.
ABSTRACT | FULL TEXT  

Quality of Life in Older Adults with HIV Disease
Avis and Smith
Research on Aging 1998;20:822-845.
ABSTRACT  

Ultrasensitive Reverse Transcription-PCR Assay for Quantitation of Human Immunodeficiency Virus Type 1 RNA in Plasma
Sun et al.
J. Clin. Microbiol. 1998;36:2964-2969.
ABSTRACT | FULL TEXT  

Antiretroviral Therapy for HIV Infection in 1998: Updated Recommendations of the International AIDS Society-USA Panel
Carpenter et al.
JAMA 1998;280:78-86.
ABSTRACT | FULL TEXT  

Line Probe Assay for Detection of Human Immunodeficiency Virus Type 1 Mutations Conferring Resistance to Nucleoside Inhibitors of Reverse Transcriptase: Comparison with Sequence Analysis
Descamps et al.
J. Clin. Microbiol. 1998;36:2143-2145.
ABSTRACT | FULL TEXT  

Goodkin et al.
CVI 1998;5:382-391.
ABSTRACT  

A Monte Carlo Simulation of Advanced HIV Disease: Application to Prevention of CMV Infection
Paltiel et al.
Med Decis Making 1998;18:S93-S105.
ABSTRACT  

Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection
Palella et al.
NEJM 1998;338:853-860.
ABSTRACT | FULL TEXT  

A Randomized, Double-blind Trial Comparing Combinations of Nevirapine, Didanosine, and Zidovudine for HIV-Infected Patients: The INCAS Trial
Montaner et al.
JAMA 1998;279:930-937.
ABSTRACT | FULL TEXT  

Predictive Value of Quantitative Plasma HIV RNA and CD4+ Lymphocyte Count in HIV-Infected Infants and Children
Palumbo et al.
JAMA 1998;279:756-761.
ABSTRACT | FULL TEXT  

Improved Survival Among HIV-Infected Individuals Following Initiation of Antiretroviral Therapy
Hogg et al.
JAMA 1998;279:450-454.
ABSTRACT | FULL TEXT  

A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs
Hertogs et al.
Antimicrob. Agents Chemother. 1998;42:269-276.
ABSTRACT | FULL TEXT  

From exceptionalism to normalisation: a reappraisal of attitudes and practice around HIV testing
De Cock and Johnson
BMJ 1998;316:290-293.
FULL TEXT  

AIDS Drug Regimens That Are Worth Their Costs
Rose
JAMA 1998;279:160-161.
FULL TEXT  

Absolute copy number and relative change in determinations of human immunodeficiency virus type 1 RNA in plasma: effect of an external standard on kit comparisons [In Process Citation]
Brambilla et al.
J. Clin. Microbiol. 1998;36:311-314.
ABSTRACT | FULL TEXT  

A Case-Control Study of HIV Seroconversion in Health Care Workers after Percutaneous Exposure
Cardo et al.
NEJM 1997;337:1485-1490.
ABSTRACT | FULL TEXT  

The Cost-Effectiveness of Fluconazole Prophylaxis against Primary Systemic Fungal Infections in AIDS Patients
Scharfstein et al.
Med Decis Making 1997;17:373-381.
ABSTRACT  

Clinical Implications of Resistance to Antiretroviral Drugs
AIDS Clin Care 1997;1997:1-1.
FULL TEXT  

Primary Care and Specialty Care in the Age of HAART
AIDS Clin Care 1997;1997:1-1.
FULL TEXT  

Postexposure Treatment of People Exposed to the Human Immunodeficiency Virus through Sexual Contact or Injection-Drug Use
Katz and Gerberding
NEJM 1997;336:1097-1100.
FULL TEXT  

Kinetics Analysis of Consecutive HIV Proteolytic Cleavages of the Gag-Pol Polyprotein
Rasnick and Rasnick
J. Biol. Chem. 1997;272:6348-6353.
ABSTRACT | FULL TEXT  

Recent advances: hiv infection–I
Cohn
BMJ 1997;314:487-487.
FULL TEXT  

New Advances in the Pharmacological Treatment of Human Immunodeficiency Virus (HIV) Infection: Focus on Protease Inhibitors
Oliphant and Bonnema
Journal of Pharmacy Practice 1997;10:20-51.
ABSTRACT  

XI International AIDS Conference: New Antiretroviral Therapy Guidelines
AIDS Clin Care 1996;1996:2-2.
FULL TEXT  

APPROACHES TO HIV THERAPY RAPIDLY EVOLVE
JWatch General 1996;1996:3-3.
FULL TEXT